NSE:LUPIN

Lupin Teams Up with Laboratorios ERN for Asthma, COPD Drug Launch in Spain

Lupin (NSE:LUPIN, BOM:500257) has partnered with Spain-based Laboratorios ERN for the launch of the Luforbec inhaler in the Spanish market, according to a Monday filing on Indian bourses.The product is a fixed-dose combination of beclometasone and formoterol for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD), the filing said.The partnership will support the commercialization of the product in Spain.Shares of Lupin fell nearly 1% in recent trade.

Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments

Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech.The US FDA has approved Ranluspec in both vials and pre-filled syringes in strengths of 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL).The drug is used to treat adults with certain sight problems, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularisation.

Lupin, Natco Win USFDA Nod for Generic Cancer Drug Eribulin Mesylate

Lupin (NSE:LUPIN, BOM:500257) and its alliance partner Natco Pharma (NSE:NATCOPHARM, BOM:524816) said the US Food and Drug Administration has approved Eribulin Mesylate injection, 1 mg/2 mL, according to a filing.The drug is a generic version of Eisai Inc.'s reference drug Halaven, the filing said. It is used for the treatment of metastatic breast cancer in patients who have received prior chemotherapy and for unresectable or metastatic liposarcoma.Halaven recorded estimated annual US sales of $43.7 million, based on IQVIA MAT April 2026 data, it added.Shares of Natco Pharma fell over 1% in Wednesday's trade.

Lupin Gets US FDA's Nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablet

Indian pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets in the strengths of 1.479 grams, 0.225 grams, and 0.188 grams.The tablets are bioequivalent to Azurity Pharmaceuticals' reference listed drug, Sutab Tablets, which are used to cleanse the colon as a preparation for colonoscopy in adults.Lupin said it is eligible for 180-day generic drug exclusivity as it was the first to file for the product, which will be manufactured at Lupin's Nagpur facility in India.IQVIA data estimates annual sales of $132.8 million for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets in the U.S. in the 12 months ended March.

Indian Equities End Lower on Wednesday as Profit Booking, Weak Rupee Weigh on Sentiment

Indian benchmark indices closed lower on Friday, ending a two-day winning streak, as profit booking intensified amid weak global cues, higher crude oil prices, and continued pressure on the rupee.The BSE Sensex fell 160.73 points, or 0.2%, to close at 75,237.99, while the NSE Nifty 50 declined 46.10 points, or 0.2%, to settle at 23,643.50.Market sentiment stayed subdued as investors tracked a sharp rise in crude oil prices and the rupee's slide to a fresh record low of over 96 rupees against the U.S. dollar. Persistent foreign outflows added to pressure on the domestic currency.In corporate developments, Indobell Insulations (BOM:544334) secured a 13.9 million rupee domestic contract from Bharat Heavy Electricals (NSE:BHEL, BOM:500103) for thermal insulation work, scheduled for completion by July 2027.Lupin (NSE:LUPIN, BOM:500257) announced the launch of Atharv Ability in New Delhi, a neuro-rehabilitation center focused on multidisciplinary treatment for neurological disorders, as per a stock exchange filing.Separately, Indian billionaire Gautam Adani and Sagar Adani reached a settlement with the U.S. Securities and Exchange Commission in a civil case, agreeing to pay civil penalties of $6 million and $12 million, respectively, without admitting or denying the allegations.

Lupin Launches New Neuro-Rehabilitation Center in New Delhi, India

Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) launched a new neuro-rehabilitation center in New Delhi, India, named Atharv Ability, according to a Friday filing to the Indian stock exchanges.The new center will offer specialized and multidisciplinary care for adults and children with neurological disabilities, including stroke, traumatic brain injury, spinal cord injury, Parkinson's disease, multiple sclerosis, and pediatric neurological disorders such as cerebral palsy.The company had earlier opened Atharv Ability centers in Mumbai in 2023 and Hyderabad in 2024.Lupin's shares were up nearly 1% in recent trade.

Phillip Securities Downgrades Lupin to Neutral from Buy; Price Target is INR2,420

Emkay Global Downgrades Lupin to Add from Buy; Price Target is INR2,500

Lupin's Consolidated Profit Rises in Fiscal Q4

Lupin's (NSE:LUPIN, BOM:500257) consolidated attributable profit rose sharply to 14.6 billion Indian rupees in the fiscal fourth quarter ended March 31, from 7.73 billion rupees. a year ago.Earnings per share came in at 31.89 rupees from 16.87 rupees a year earlier, the pharmaceutical company said in a filing with the Indian stock exchanges on Thursday.Revenue from operations in fiscal Q4 increased to 74.7 billion rupees from 56.7 billion rupees a year ago.The company's board declares a dividend of 18 rupees per equity share of face value of 2 rupees each, fully paid up, for the financial year ended March 31.

Lupin Gets US FDA Nod for Glycerol Phenylbutyrate Oral Liquid

Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for Glycerol Phenylbutyrate Oral Liquid, according to a Tuesday filing to the Indian stock exchanges.Glycerol Phenylbutyrate Oral Liquid is bioequivalent to Horizon Therapeutics U.S. Holding's reference-listed drug Ravicti Oral Liquid, which is used to treat chronic management of patients with urea cycle disorders.Sales for glycerol phenylbutyrate oral liquid were $337 million for the year ended December 2025, according to IQVIA's estimates.

Lupin Launches Dapagliflozin and Metformin Hydrochloride Tablets in US

Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, according to a Wednesday filing to the Indian stock exchanges.The company launched the drug following the approval from the U.S. Food and Drug Administration as bioequivalent to AstraZeneca AB's Xigduo XR.The company's shares were down nearly 1% in recent trade.